Revance Therapeutics, Inc.
http://www.revance.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Revance Therapeutics, Inc.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
Many Firsts Among The Drugs That Launched In 2023
Drug launches in 2023 included some groundbreaking innovations, but that didn’t necessarily translate to quick commercial success.
A Year Of Change: Viatris Ploughs Ahead With Brand Ambitions
In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.
Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival
The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Essentia Biosystems, Inc.
- HintMD
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice